S

Samil Pharmaceutical Co Ltd
KRX:000520

Watchlist Manager
Samil Pharmaceutical Co Ltd
KRX:000520
Watchlist
Price: 10 170 KRW -1.07% Market Closed
Market Cap: 220.6B KRW

Samil Pharmaceutical Co Ltd
Income from Continuing Operations

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Samil Pharmaceutical Co Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
S
Samil Pharmaceutical Co Ltd
KRX:000520
Income from Continuing Operations
-â‚©19.8B
CAGR 3-Years
-61%
CAGR 5-Years
N/A
CAGR 10-Years
-12%
Yuhan Corp
KRX:000100
Income from Continuing Operations
â‚©66.4B
CAGR 3-Years
-11%
CAGR 5-Years
-17%
CAGR 10-Years
-4%
SK Biopharmaceuticals Co Ltd
KRX:326030
Income from Continuing Operations
â‚©241.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Income from Continuing Operations
â‚©117.8B
CAGR 3-Years
6%
CAGR 5-Years
22%
CAGR 10-Years
10%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Income from Continuing Operations
-â‚©9.6B
CAGR 3-Years
-99%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Caregen Co Ltd
KOSDAQ:214370
Income from Continuing Operations
â‚©30B
CAGR 3-Years
5%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
No Stocks Found

Samil Pharmaceutical Co Ltd
Glance View

Market Cap
215.9B KRW
Industry
Pharmaceuticals

SAMIL PHARMACEUTICAL Co., Ltd. engages in the development and manufacture of pharmaceutical products. The company is headquartered in Seoul, Seoul. The Company’s products portfolio consists of gastro-intestinal drugs such as antiulcerants, gastroprokinetic agents, digestive enzymes with nutrients and laxatives under the brand names of Plybutine, Gliptide and others; antipyretic, analgesic and anti-inflammatory agents under the brand name Brufen; nutritional supplements such as vitamins, minerals and immunosuppressants, and others including antigout agents, anti-parkinsonism agents and others. In addition, it is engaged in the provision of miscellaneous goods. The firm distributes its products within domestic market and to overseas markets. On November 29, 2013, it transferred its entire shares of a Korea-based company, which is engaged in the sale of medical products.

Intrinsic Value
9 363.63 KRW
Overvaluation 8%
Intrinsic Value
Price
S

See Also

What is Samil Pharmaceutical Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
-19.8B KRW

Based on the financial report for Jun 30, 2025, Samil Pharmaceutical Co Ltd's Income from Continuing Operations amounts to -19.8B KRW.

What is Samil Pharmaceutical Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-12%

Over the last year, the Income from Continuing Operations growth was -1 615%. The average annual Income from Continuing Operations growth rates for Samil Pharmaceutical Co Ltd have been -61% over the past three years , and -12% over the past ten years .

Back to Top